Drugs / PEXIPEPIMUT-S
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05232851 | Jun 2022 → Apr 2025 overdue | human papillomavirus-related squamous cell carcinoma, oropharyngeal carcinoma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04287868 | Jun 2020 → Jul 2022 | anal carcinoma, cervical cancer, oropharyngeal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07090174 | Oct 2025 → Jul 2026 overdue | HIV infectious disease, anal carcinoma, cervical cancer, human papilloma virus infection +1 | Weill Medical College of Cornell University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04260126 | Mar 2021 → May 2025 | oropharynx squamous cell carcinoma | PDS Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT04580771 | Oct 2020 → Mar 2027 expected | cervical cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06790966 | May 2025 → Feb 2029 expected | oropharynx squamous cell carcinoma | PDS Biotechnology Corp. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEXIPEPIMUT-S | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095479 ↗ |
| Known as | PDS0101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06790966 ↗ |
| Action | Activate | “by activating multiple immune pathways” NCT04260126 ↗ |
| Modality | Vaccine | “the HPV type 16 therapeutic vaccine PDS0101” PMID 39976981 ↗ Apr 2025 |
| Route | Subcutaneous | “two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12” NCT04260126 ↗ |